Effect of darifenacin on fecal incontinence in women with double incontinence

Kissane, Lindsay M; Martin, Kimberly; Meyer, Isuzu; Richter, Holly E.

doi:10.1007/s00192-020-04369-3

Cited by 6 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the prevalence of DI was much higher among the patients with FI than among the general population. Recently, targeted intervention programs, such as pelvic floor physical therapy and antimuscarinic medications, have been devised that can be effective for both FI and UI [39,44]. However, the overall rate of medical consultations for LUTS is reported to be as low as 18.0%, and is especially low at 9.0% among women [21].…”

Section: Discussionmentioning

confidence: 99%

Prevalence of Double Incontinence and Lower Urinary Tract Symptoms in Patients with Fecal Incontinence: A Single-center Observational Study

Abe,

Matsumoto,

Kunimoto

et al. 2024

J Anus Rectum Colon

View full text Add to dashboard Cite

Objectives: Double incontinence (DI), which is the co-occurrence of fecal incontinence (FI) and urinary incontinence (UI), increases with age and has a greater negative impact on the quality of life (QOL) than either incontinence alone. We aimed to assess lower urinary tract symptoms (LUTS) in patients with FI to elucidate the prevalence and characteristics of DI. Methods: This study enrolled consecutive patients who visited our hospital with FI symptoms. FI was evaluated using the Cleveland Clinic Florida Fecal Incontinence Score (CCFIS). LUTS were assessed using the International Prostate Symptom Score (IPSS), QOL score (IPSS-QOL) and Overactive Bladder Symptom Score (OABSS). Results: This study evaluated 140 patients (96 women [mean age: 70.7 years] and 44 men [mean age: 74.4 years]). The mean IPSS was significantly higher in men than in women (12.0 vs. 7.5, p = 0.003). A positive correlation was found between IPSS and CCFIS in women (r = 0.256, p = 0.012) but not in men. For both sexes, the older group (aged ≥70 years) had higher OABSS scores and more urge UI instances than the younger group (aged ≤69 years). Of the 140 patients with FI, 78 (55.7%) had DI, and DI was more common in women than in men (63.5% vs. 38.6%, p = 0.006). Conclusions: The characteristics of LUTS and UI in patients with FI were comparable to those in the general population for both sexes; however, the prevalence of DI was much higher among patients with FI than that in the general population.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence of Double Incontinence and Lower Urinary Tract Symptoms in Patients with Fecal Incontinence: A Single-center Observational Study

Abe,

Matsumoto,

Kunimoto

et al. 2024

J Anus Rectum Colon

View full text Add to dashboard Cite

show abstract

“…Other drugs, not originally indicated for FI, have also been studied. Darifenacin has, for example, been tested as an early invention for FI in women with double incontinence (32 participants, no control group) and may merit further exploration in the context of a randomised controlled trial 31…”

Section: Discussionmentioning

confidence: 99%

Future developments and new technologies in the field of faecal incontinence: scanning the horizon using late-stage clinical trial registrations

et al. 2022

View full text Add to dashboard Cite

AimThe aim of this study was to examine how new technologies in late-stage clinical trials might address unmet patient, practitioner or caregiver need for faecal incontinence (FI) over the next 5 years.MethodsHorizon scanning techniques were used to provide insights into the current landscape of emerging health technologies. A search was performed across clinical trial registries using the National Institute for Health Research Innovation Observatory’s ScanMedicine database (scanmedicine.com) to identify new, emerging interventions or health technologies (drugs, medical devices or diagnostics) that were addressing or investigating FI. Trials were then screened for relevance to FI in a non-blinded duplicate manner.Results1163 records were identified through searching ScanMedicine, and 136 trials were included in the final data extraction and mapping process. The most frequently investigated FI intervention topics were complementary therapies (n=17, 12.4%); electrical stimulation (n=13, 9.5%); pelvic floor muscle training/biofeedback/sphincter exercises (n=13, 9.5%) and implanted sacral nerve stimulation (n=12, 8.7%). There was little evidence of new pharmaceutical technologies in development. Existing drugs are, however, being repurposed and trialled for the treatment of FI (eg, linaclotide, colesevelam). Such repurposed drugs often have lower development costs, shorter timelines and report lower failure rates compared with new pharmaceutical products.ConclusionOverall, the innovation space as indicated by late-stage clinical trials related to FI, is relatively stagnant. Patients, carers and healthcare professionals are demanding more effective treatment and containment options; however, these are unlikely to come to market in the immediate future.

show abstract

The impact of urinary incontinence on multiple health outcomes: an umbrella review of meta-analysis of observational studies

et al. 2023

View full text Add to dashboard Cite

Effect of darifenacin on fecal incontinence in women with double incontinence

Cited by 6 publications

References 25 publications

Prevalence of Double Incontinence and Lower Urinary Tract Symptoms in Patients with Fecal Incontinence: A Single-center Observational Study

Prevalence of Double Incontinence and Lower Urinary Tract Symptoms in Patients with Fecal Incontinence: A Single-center Observational Study

Future developments and new technologies in the field of faecal incontinence: scanning the horizon using late-stage clinical trial registrations

The impact of urinary incontinence on multiple health outcomes: an umbrella review of meta-analysis of observational studies

Contact Info

Product

Resources

About